Where does ImmuneBridge's cap table come from?

Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across ImmuneBridge's 2 recorded funding rounds.

Premier Alternatives

ImmuneBridge

San Francisco, CA · Founded 2018 · Privately Held (backing)

Developer of allogeneic cellular immunotherapies designed for advancing cancer treatment. ImmuneBridge is based in San Francisco, CA and was founded in 2018. Its last reported valuation was $25 million in Jan 2023. It has raised $19.7 million across 2 recorded rounds; the latest was a $5.6 million early-stage round in Mar 2025.

Last reported valuation

$25.0M

Oct 2026

Priced at

—

Total raised

$19.7M

Last round

Early Stage VC

Mar 2025

Cap table — not yet on record

ImmuneBridge's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.

Pro members can request priority coverage with a 48-hour turnaround.

Free account

More of ImmuneBridge with a free account

·The complete investor list: 16 names
·Watch ImmuneBridge: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Frequently asked about ImmuneBridge

Where does ImmuneBridge's cap table come from?: Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across ImmuneBridge's 2 recorded funding rounds.